# Enanta Pharmaceuticals to Present Phase 2 Zelicapavir RSV Data at IDWeek 2026

- URL: https://stocks.freetheai.org/news/enanta-pharmaceuticals-to-present-phase-2-zelicapavir-rsv-data-at-idweek-2026-db0ea5
- Published: 2026-10-13T11:00:00Z
- Category: company_news; sentiment: neutral; impact: low
- Symbols: [NASDAQ:ENTA](https://stocks.freetheai.org/symbols/NASDAQ-ENTA)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will present clinical trial results for zelicapavir, its oral, once-daily treatment candidate for respiratory syncytial virus (RSV), at the IDWeek 2026 conference in October.

The poster presentation will share Phase 2 trial data from a global study involving high-risk adults. The study examined how zelicapavir affected the time to complete RSV symptom resolution, hospitalization rates, and viral load compared with a placebo.

The presentation by Dr. Christopher E. Harris is scheduled for October 22, 2026, in Washington, D.C. Shares of Enanta Pharmaceuticals were trading at $12.30, down 1.60% today.

## Key points

- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will present Phase 2 clinical trial data for zelicapavir at IDWeek 2026 on October 22, 2026.
- Zelicapavir is an experimental oral, once-daily N-protein inhibitor under development to treat respiratory syncytial virus (RSV).
- The Phase 2 trial evaluated zelicapavir's effects on RSV symptom resolution, hospitalization, and viral load in high-risk adults versus placebo.
- Dr. Christopher E. Harris will present the findings during the Novel Agents poster session at the conference in Washington, D.C.

## Questions and answers

### When is Enanta Pharmaceuticals presenting its RSV drug data?

Enanta Pharmaceuticals will present Phase 2 data for zelicapavir on October 22, 2026, between 12:15 PM and 1:30 PM ET at IDWeek 2026 in Washington, D.C.

### What is zelicapavir?

Zelicapavir is an investigational oral, once-daily N-protein inhibitor being developed by Enanta Pharmaceuticals to treat respiratory syncytial virus (RSV).

### What did the Phase 2 trial of zelicapavir measure?

The Phase 2 trial evaluated zelicapavir in high-risk adults with RSV, measuring its effect on symptom resolution, hospitalization, and viral load compared to a placebo.